Supplementary Data — Bemnifosbuvir for COVID-19: real-time meta analysis of 4 studies

@CovidAnalysis, November 2025, Version 4V4
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ MOONSONG Boffito (DB RCT) 3% 0.97 [0.93-1.01] viral load 29 (n) 40 (n) Improvement, RR [CI] Treatment Control MOONSONG Boffito (DB RCT) 7% 0.93 [0.89-0.96] viral load 29 (n) 29 (n) MORNINGSKY Horga (DB RCT) 71% 0.29 [0.09-0.96] hosp. 4/137 7/70 MORNINGSKY Horga (DB RCT) 28% 0.72 [0.33-1.53] progression 14/137 10/70 MORNINGSKY Horga (DB RCT) 23% 0.77 [0.28-2.07] no recov. 9/137 6/70 MORNINGSKY Horga (DB RCT) 22% 0.78 [0.54-1.12] viral+ 44/128 29/66 SUNRISE-3 Hammond (DB RCT) -202% 3.02 [0.32-29.0] death 3/1,130 1/1,139 SUNRISE-3 Hammond (DB RCT) -253% 3.53 [0.73-17.0] hosp. 7/1,058 2/1,067 SUNRISE-3 Hammond (DB RCT) -102% 2.02 [0.37-11.0] hosp. 4/1,058 2/1,067 SUNRISE-3 Hammond (DB RCT) 24% 0.76 [0.32-1.79] misc. 9/1,058 12/1,067 Horga (DB RCT) 86% 0.14 [0.01-2.71] death 0/41 3/42 Horga (DB RCT) 27% 0.73 [0.17-3.06] progression 3/41 4/40 Horga (DB RCT) 2% 0.98 [0.41-2.35] no recov. 8/41 8/40 Horga (DB RCT) 9% 0.91 [0.54-1.51] viral+ 13/27 17/32 Bemnifosbuvir COVID-19 outcomes c19early.org November 2025 Favors bemnifosbuvir Favors control
Fig. S1. All outcomes.